Drugs / SEEMORE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01989195 | May → Jun 2013 | cardiomyopathy | Stanford University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEEMORE | “ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT” NCT01989195 ↗ |
| Modality | Diagnostic / imaging agent | “SeeMore is a new manganese (Mn)-based intravenous imaging agent being developed to enhance magnetic resonance imaging (MRI).” NCT01989195 ↗ |
| Route | Intravenous | “SeeMore™ will be administered intravenously over approximately one minute.” NCT01989195 ↗ |